Bausch + Lomb (BLCO) – Investment Analysts’ Recent Ratings Updates

Bausch + Lomb (NYSE: BLCO) has recently received a number of price target changes and ratings updates:

• 8/7/2026 – Bausch + Lomb was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/3/2026 – Bausch + Lomb had its price target raised by HC Wainwright from $20.00 to $21.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Bausch + Lomb is now covered by UBS Group AG. They set a “buy” rating and a $21.00 price target on the stock.
• 7/28/2026 – Bausch + Lomb is now covered by UBS Group AG. They set a “buy” rating and a $21.00 price target on the stock.
• 7/28/2026 – Bausch + Lomb is now covered by UBS Group AG. They set a “buy” rating and a $21.00 price target on the stock.
• 7/24/2026 – Bausch + Lomb was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/9/2026 – Bausch + Lomb was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 7/8/2026 – Bausch + Lomb had its price target raised by Citigroup Inc. from $19.00 to $21.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Bausch + Lomb was given a new $17.00 price target by Evercore Inc.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.